The majority of gastrointestinal stromal tumors is characterized by oncogenically activating mutations of the KIT receptor tyrosine kinase and can hence successfully be treated with the KIT inhibitor imatinib mesylate. The gene discussed is NTRK1; the disease is gastrointestinal stromal tumor.